CLDXCelldex Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $38.71 · now $38.71 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, CLDX has typically landed between $30.57 and $49.15 — a range of −21.0% to +27.0% from the issuance price $38.71.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

5,000 overlapping 1 month windows · 2006-09-262026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($38.71) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where CLDX has typically landed a month from the 2026-09-16 close of $38.71 — the range is history, not a prediction.

$30.57worst · -21.0%$49.15best · +27.0%
  • now $38.71 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $38.48 (-0.6%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $34.65$42.3
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $30.57$49.15
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 5,000 windows spanning 2006-09-26 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2018-03-21−72.0%−72.4%+0.0%
2018-03-19−71.5%−71.5%+2.9%
2018-03-20−71.2%−72.0%+1.2%
3 best
2020-05-18+473.1%+0.0%+473.1%
2020-05-19+436.6%+0.0%+463.4%
2020-05-29+401.1%−0.4%+402.2%

5,000 overlapping windows · 2006-09-262026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
45%
+10.3%
n=20
Feb
60%
+4.1%
n=20
Mar
55%
−3.3%
n=20
Apr
50%
+1.0%
n=20
May
30%
−4.4%
n=20
Jun
55%
+20.1%
n=20
Jul
55%
+1.0%
n=20
Aug
50%
−3.8%
n=20
Sep
45%
+1.1%
n=20
Oct
50%
−3.8%
n=20
Nov
70%
+8.2%
n=20
Dec
40%
−1.8%
n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$45$212025-12-04: 1 insider sale, $121K — Jimenez Freddy A.2025-11-13: 1 insider sale, $1.2M — Wright Richard M.2025-08-13: 2 insider sales, $19K — Jimenez Freddy A. …2025-08: 2 open-market sales, $19K2025-11: 1 open-market sale, $1.2M2025-12: 1 open-market sale, $121K↑ buys↓ salesofficer Jimenez Freddy A. — Sale on 2025-12-04, filed 4 days after the tradeother Wright Richard M. — Sale on 2025-11-13, filed 4 days after the tradeofficer Jimenez Freddy A. — Sale on 2025-08-13, filed 2 days after the tradeofficer Jimenez Freddy A. — Sale on 2025-08-13, filed 2 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-12-04Jimenez Freddy A.officerSale4,166 @ $29.09$121K−11.9% of holding−12.6%−12.1%30,796Form 4 · filed 4 days after the trade
2025-11-13Wright Richard M.otherSale49,298 @ $24.00$1.2M−70.3% of holding+12.9%+16.9%20,833Form 4 · filed 4 days after the trade
2025-08-13Jimenez Freddy A.officerSale430 @ $25.41$11K−1.2% of holding−4.1%−11.9%34,962Form 4 · filed 2 days after the trade
2025-08-13Jimenez Freddy A.officerSale341 @ $23.95$8K−1.0% of holding−4.1%−11.9%35,392Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

48 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-25Jimenez Freddy A.officerAward / grant93,00093,000Form 4
2026-06-25Lawver Teri LdirectorAward / grant90,00090,000Form 4
2026-06-25Brownlie Keith LdirectorAward / grant26,00026,000Form 4
2026-06-25CONRAD HERBERT JdirectorAward / grant26,00026,000Form 4
2026-06-25Cavanaugh SarahofficerAward / grant95,00095,000Form 4
2026-06-25PENNER HARRY JRdirectorAward / grant26,00026,000Form 4
2026-06-25MARINO JAMES JdirectorAward / grant26,00026,000Form 4
2026-06-25PEPIN RONALDofficerAward / grant20,00020,000Form 4
2026-06-25KELER TIBORofficerAward / grant115,000115,000Form 4
2026-06-25Marucci Anthony SdirectorAward / grant375,000375,000Form 4
2026-06-25Cohen CheryldirectorAward / grant26,00026,000Form 4
2026-06-25NEIL GARRY ARTHURdirectorAward / grant26,00026,000Form 4
2026-06-25Young Diane C.officerAward / grant57,00057,000Form 4
2026-06-25Crowley ElizabethofficerAward / grant100,000100,000Form 4
2026-06-25Jain RitadirectorAward / grant26,00026,000Form 4
2026-06-25Martin Samuel BatesofficerAward / grant93,00093,000Form 4
2026-06-25Heath-Chiozzi MargoofficerAward / grant95,00095,000Form 4
2026-06-25Torres DenicedirectorAward / grant26,00026,000Form 4
2026-01-02Martin Samuel BatesofficerOption exercise4,81732,942Form 4
2026-01-02Martin Samuel BatesofficerOption exercise4,81758,815Form 4
2025-12-15PEPIN RONALDofficerOption exercise8,3339,097Form 4
2025-12-15PEPIN RONALDofficerOption exercise11,00020,097Form 4
2025-12-15PEPIN RONALDofficerOption exercise11,0000Form 4
2025-12-15PEPIN RONALDofficerOption exercise8,3335,000Form 4
2025-11-13Wright Richard M.otherOption exercise15,75070,131Form 4
2025-11-13Wright Richard M.otherOption exercise26,67254,381Form 4
2025-11-13Wright Richard M.otherOption exercise6,87627,709Form 4
2025-11-13Wright Richard M.otherOption exercise15,7507,875Form 4
2025-11-13Wright Richard M.otherOption exercise6,8760Form 4
2025-11-13Wright Richard M.otherOption exercise26,6720Form 4
2025-11-10Lawver Teri LdirectorAward / grant100,000100,000Form 4
2025-06-05Heath-Chiozzi MargoofficerAward / grant82,00082,000Form 4
2025-06-05CONRAD HERBERT JdirectorAward / grant16,50016,500Form 4
2025-06-05MARINO JAMES JdirectorAward / grant16,50016,500Form 4
2025-06-05Cavanaugh SarahofficerAward / grant78,00078,000Form 4
2025-06-05Brownlie Keith LdirectorAward / grant16,50016,500Form 4
2025-06-05NEIL GARRY ARTHURdirectorAward / grant16,50016,500Form 4
2025-06-05Torres DenicedirectorAward / grant33,00033,000Form 4
2025-06-05Young Diane C.officerAward / grant72,00072,000Form 4
2025-06-05Cohen CheryldirectorAward / grant16,50016,500Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.